Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abbott
• Treatments: Atrasentan; Hormones

Criteria

Inclusion Criteria:

• Have been diagnosed with prostate cancer.

• Have a rising PSA while on hormone therapy or following surgical castration.

Exclusion Criteria:

• Have evidence of distant metastatic disease on screening bone scan or CT scan.

• Have received cytotoxic chemotherapy.

• Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.